Contact

News

Stay up to date on ReAlta’s news, scientific progress, clinical milestones, and mission to address severe inflammatory disease.
Press Release
Apr 08, 2026

ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod Phase 2 Program in Hypoxic Ischemic Encephalopathy (HIE)

Press Release
Apr 04, 2022
ReAlta Life Sciences’ RLS-0071 Demonstrates Excellent Safety Profile and Confirmed Target Engagement in First-in-Human Phase 1 Clinical Trial
Press Release
Mar 30, 2022
FDA Clears ReAlta Life Sciences' Phase 2 STAR Trial of RLS-0071 in Neonates with Hypoxic-Ischemic Encephalopathy
ABSTRACT
Feb 09, 2022
The EPICC Family of Anti-Inflammatory Peptides: Next Generation Peptides, Additional Mechanisms of Action, and In Vivo and Ex Vivo Efficacy
ABSTRACT
Oct 07, 2021
Classical complement pathway inhibition reduces brain damage in a hypoxic ischemic encephalopathy animal model
Press Release
Feb 16, 2021
ReAlta Life Sciences Doses First Subject In Phase 1 Healthy Volunteers Study Of RLS-0071
Press Release
Dec 03, 2020
ReAlta Life Sciences Announces EMA Orphan Drug Designation for RLS-0071 For The Treatment Of Neonatal Encephalopathy
1 2 3 4